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AbstrACt 
Objectives To understand patterns of subcutaneous 
(SC) biologics use over time in adults with inflammatory 
rheumatic musculoskeletal diseases receiving a homecare 
delivery service.
Design Retrospective cohort.
setting Patients in secondary care receiving SC biologics 
in the largest Scottish Health Board.
Participants A new bespoke cohort was created from 
routine data gathered as part of a health board Homecare 
Service Database. Patients over 18 years who received a 
supply of SC biologic from January 2012 to May 2015 with 
a diagnosis for rheumatoid arthritis (RA), psoriatic arthritis 
(PsA) or ankylosing spondylitis (AS) were included.
Outcomes measured A standardised framework was 
applied by measuring discontinuation rates, persistence 
using Kaplan-Meier analysis and Cox regression and 
adherence using medication refill adherence (MRA) and 
compliance rate (CR).
results 751 patients were identified (AS: 105, PsA: 227, 
RA: 419) of whom 89.3% had more than one biologic 
delivery (median days’ follow-up: AS: 494; PsA: 544; RA: 
529) and 83.2% did not switch biologic. For all conditions, 
approximately half were persistent on their index biologic 
(52% AS, 54% PsA, 48%RA). Of patients who discontinued 
treatment, the majority reinitiated with the same biologic 
(19% AS, 18% PsA and 21% RA). Overall adherence during 
the period of treatment was over 80% when calculated 
using MRA (median %MRA: AS: 84.0%, PsA: 85.0%, RA: 
82.4%) or CR (median %CR: AS: 96.6%, PsA: 97%, RA: 
96.6%).
Conclusion Use of linked routine data is a sustainable 
pathway to enable ongoing evaluation of biologics use. A 
more consistent approach to studying use (discontinuation, 
persistence and adherence metrics) should be adopted to 
enable comparability of studies.
IntrODuCtIOn
Chronic inflammatory rheumatic musculo-
skeletal diseases such as rheumatoid arthritis 
(RA), psoriatic arthritis (PsA) and ankylosing 
spondylitis (AS) are characterised by inflam-
matory joint symptoms requiring long-term 
management. Over the past two decades, the 
use of biologic therapies has revolutionised 
their treatment, with national and global 
groups recommending their use in patients 
with moderate to severe disease unrespon-
sive to conventional therapies.1–5While 
clinical trials have demonstrated their short-
term efficacy and safety, long-term evidence 
requires observational studies and real-world 
data. Despite reassuring results to date,6–10 
important challenges and unanswered ques-
tions remain. 
Furthermore, despite the apparent shared 
inflammatory mechanisms and therapies, 
there are significant differences between 
these inflammatory conditions in terms of 
prevalence, gender and sex distribution, 
strengths and limitations of this study
 ► This is the first real-world cohort containing type, 
frequency and dose of seven subcutaneous biologics 
delivered directly to patients with ankylosing spon-
dylitis, psoriatic arthritis and rheumatoid arthritis.
 ► The cohort is sustainable being generated as part 
of routine clinical care, can be easily updated and 
linked to other administrative datasets and provides 
a novel way to assess adherence, persistence and 
discontinuation of biologics.
 ► The limitations include having a mixed cohort of 
naive and existing biologic users, not capturing 
reasons for variability in patients’ response, use of 
intravenous biologics or prior use of any biologic or 
subcutaneous methotrexate.
 ► The generalisability of the results in a Scottish set-
ting has to be tested, as this cohort covers the larg-
est Scottish Health Board.
Protected by copyright.
 o
n
 Septem
ber 9, 2019 at University of Strathclyde Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027059 on 4 September 2019. Downloaded from 
2 Alvarez-Madrazo S, et al. BMJ Open 2019;9:e027059. doi:10.1136/bmjopen-2018-027059
Open access 
genetics, pathophysiology and clinical phenotype, 
including extra-articular manifestations and comorbidi-
ties.11–16 Therefore, the safety and long-term therapy data 
for one condition (usually RA due to the larger numbers 
and longer pharmacological history) cannot simply be 
assumed to apply to the other conditions, even for the 
same drug. It is therefore important to evaluate these 
factors in real-world settings across the range of condi-
tions for which these drugs are used.
In addition to drug and disease-related factors, in clin-
ical practice, poor adherence and persistence to therapy 
are important detrimental factors, contributing to treat-
ment failure and disease progression.17 Most of the direct 
comparisons for adherence and persistence are from 
observational studies, mainly focusing on the first biologic 
to reach the market/clinical practice (infliximab, adali-
mumab and etanercept).17–19 A few studies have incor-
porated other biologics,20–26 with more biologics set to 
be approved in the upcoming years. Although the stan-
dardised measurement of adherence and persistence, 
dividing the process in three phases—initiation, imple-
mentation and discontinuation—has been advocated by 
Vrijens et al and endorsed by the European Society for 
Patient Adherence, Compliance and Persistence (ESPA-
COMP),27 this methodology has mainly been applied to 
oral medications and not to biologics, which are admin-
istered subcutaneously or intravenously, with complex 
dosing schedules.
Disease or drug registers are expensive, labour inten-
sive and not optimal for evaluating adherence and 
persistence, so other methods are required.17 18 In many 
countries, administrative or prescription datasets linked 
to reimbursement have been used,28–31 but these do not 
always indicate whether the participant actually received 
the medication. Furthermore, biologics usually require 
specialist prescription so are not routinely captured in 
primary care prescription datasets.
This study aimed to use a homecare service database 
for subcutaneous biologics to understand the patterns of 
their use over time in a population of adults with rheu-
matic diseases.
MethODs
Data sources
For this study, a new bespoke, retrospective cohort of 
patients receiving subcutaneous biologics was created 
by linking administrative electronic health records at 
a patient level via a unique national (Scottish) health 
service identifier, known as the Community Health 
Index.32 This dataset included two resources available in 
the largest Scottish Health Board, NHS Greater Glasgow 
and Clyde (GGC), with a population covering 1.2 million 
of the 5.4 million residents in Scotland.33 The two novel 
resources were the Homecare Service Database (HSD) 
and the local Rheumatology Arthritis Database (RAD), 
in addition to three existing nationally held datasets: the 
Prescribing Information System (PIS),34 the mortality 
records (National Records of Scotland (NRS)) and the 
Scottish Morbidity Records (SMR01).35 The variables 
obtained from each dataset are outlined in figure 1.
Of the GGC patients receiving biologics up until early 
2018, 98% received subcutaneous biologics uniquely 
via the homecare delivery route, with delivery details 
captured in the HSD and managed through the phar-
macy distribution system in the health board. Since 2012, 
the HSD has systematically captured information about 
patients (eg, hospital attended, indication for biologics, 
drugs and dose, administration and delivery frequency, 
date and quantity delivered), prescribers and health-
care delivery companies. The remaining 2% of patients 
receiving intravenous biologics are not captured in the 
HSD as these medicines are administered directly in 
hospital day wards.
The RAD contains information of patients who have 
attended rheumatology clinics in two of the four main 
hospitals in Glasgow since 1997. Diverse clinical variables 
are recorded, including the main and secondary diag-
noses, biologic screening/follow-up, comorbidities, other 
medications and lifestyle factors.
The PIS includes prescriptions prescribed, dispensed 
and reimbursed within the community setting,34 NRS 
captures cause-specific mortality records and SMR01 has 
episode-level data on all hospital inpatient and day care 
episodes from hospitals in Scotland.35
study population
Patients who received at least one delivery of subcuta-
neous biologics in the HSD dataset with a diagnosis for 
AS, PsA or RA were eligible for this study. The RAD data-
base was used to validate the diagnosis in a subset of HSD 
patients (see online supplementary file and supplemen-
tary figure 1 for validation methods and results).
All patients who had a biologic supply date between 
January 2012 and May 2015 and were at least 18 years 
Figure 1 Variables obtained from different Scottish 
datasets. AS, ankylosing spondylitis; HSD, Homecare Service 
Database; PsA, psoriatic arthritis; RA, rheumatoid arthritis; 
RAD, Rheumatology Arthritis Database; SMC, Scottish 
Medicines Consortium.
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old at cohort entry were included. All patients were 
followed-up until death, migration to a primary care prac-
tice outside Scotland or end date of the study (May 2015), 
whichever occurred first. In the overall cohort, both prev-
alent and incident users were included (n=751, 105 AS, 
227 PsA and 419 RA). To illustrate the stability of find-
ings, a subset analysis was carried out with only incident 
users (n=673, 95 AS, 208 PsA and 370 RA), defined as 
patients who did not receive a subcutaneous biologic in 
the first 6 months of the study period (from January to 
June 2012) (online  supplementary file).
One patient was excluded as its first biologic delivery 
was prior to the date of approval for the drug by the Scot-
tish Medicines Consortium, which is the national health 
technology assessment process for all new medicines in 
Scotland.36 Also two patients having all missing records 
in the HSD for dose, frequency or how often the delivery 
of the biologics would take place were deleted to enable 
calculations of weeks covered per delivery in the rest the 
cohort.
The first delivery date for any biologic was established 
as the index date and the first biologic recorded was 
considered the index biologic. Age was calculated at 
index date. Socioeconomic status was assessed using the 
Scottish Index of Multiple Deprivation quintile (SIMD) 
2012 quintiles, a measure that incorporates different 
aspects of deprivation into a single index. Patients with 
missing SIMD values remained in the cohort. To assess 
comedication, patients with at least one prescription in 
the 12 months prior to the index date in PIS for antibac-
terials (British National Formulary (BNF) section 5.1), 
antifungals (BNF section 5.2), antivirals (BNF section 
5.3), oral methotrexate (prescribed item methotrexate), 
disease-modifying antirheumatic drugs (DMARDs; BNF 
subsection 10.1.3), non-steroidal anti-inflammatory drugs 
(NSAIDs; BNF subsection 10.1.1) and corticosteroids 
(BNF subsections 1.5.2 or 6.3.2) were recorded.
Data analyses
Patients characteristics were summarised using descrip-
tive statistics. Medians and IQRs are provided for contin-
uous variables, and global comparisons were done using 
the Kruskal-Wallis test. Numbers and percentages are 
provided for categorical variables, and global compar-
isons were done using either χ2 test or Fisher’s exact 
test (in cases where cells had expected frequencies <5). 
To protect confidentiality in the results, the GGC Safe 
Haven carried out a statistical disclosure control. The 
cell suppression method was applied when the cell values 
were small and there was a risk of disseminating sensitive 
information.37
In this study, we advocate the use of a standardised 
framework that includes measurements of discontinua-
tion, persistence and adherence.27 38
Considering the variation in the administration 
frequencies and number of injections delivered according 
to biologic, first the estimated days covered per delivery 
was calculated by multiplying the quantity delivered by 
the standard administration frequency according to the 
approved licence for each biologic. Knowing the delivery 
date and the estimated days covered allowed estimation 
of the expected end date covered and how it related with 
the following delivery and whether there were gaps or not. 
These metrics were the basis of the utilisation analysis.
Discontinuation was defined as the end of treatment, 
either because there was a considerable gap of more than 
56 days between deliveries (reinitiation) or no more deliv-
eries were received (cessation). Those who did not discon-
tinue were defined as persistent. Discontinuation rates 
were estimated using the refill-gap method.39 Patients were 
censored at first discontinuation, predefined as a gap of 
more than 56 days with no biologics delivery after exhaus-
tion of the days’ supplied by the previous delivery, regard-
less of whether patients switched to another biologic. This 
gap was selected because most biologics were delivered 
bimonthly, approximately five times the half-life for the 
biologics of interest would have elapsed, and this was 
comparable with other studies.26 29 A sensitivity analysis 
was conducted using a gap of 28 days (minimum period 
between deliveries) and 84 days (maximum period 
between deliveries) (see online supplementary file).
Crude persistence was estimated using Kaplan-Meier 
analysis, and Cox regression was used to assess persistence 
postindex date, in patients with at least 6 months 
follow-up. The proportional hazards (PHs) assumption 
for a Cox regression model was tested in both the crude 
and the adjusted model and stratified where appropriate 
to ensure a non-significant global p value.40 Patients who 
died or migrated were censored.
The hazard ratios (HRs) for persistence with biologics 
were adjusted for sex, age, SIMD, use of index biologic or 
not (meaning a switch could have happened while being 
persistent), use of oral methotrexate in the 12 months 
before to the index date and concomitant use of oral 
methotrexate or DMARD during study period.
Adherence is defined as to what extent the biologics 
delivered correspond to the treatment regimen recom-
mended in the BNF. There is no consensus in the liter-
ature on how best to estimate adherence thus two 
measurements were used for patients with at least two 
deliveries of the index biologic: medication refill adher-
ence (MRA) and compliance rate (CR).38 41 MRA gives 
an overall adherence percentage describing the expo-
sure during the whole study period regardless of the time 
when the last prescription was delivered and is calcu-
lated as (total days’ supply/total days in study) × 100. In 
contrast, CR describes the exposure between first and last 
prescription delivered (total days’ supply excluding last 
delivery/days from first delivery up to but not including 
last delivery) × 100.
Analyses were performed in R software, V.3.5.0.42
Patient and public involvement
The prelimary design of this study was presented to the 
Farr Scotland Public Panel. According to their experience 
and preferences, the research questions and outcome 
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measures were developed to make the results generalis-
able to patients with rheumatic conditions.
results
The study included 751 patients: 105 with AS, 227 with 
PsA and 419 with RA (table 1). From them, 673 patients 
(89.6%) were incident users, 95 AS (90.5%), 208 PsA 
(91.6%) and 370 RA (88.3%). The patients with RA were 
older and had a higher proportion of females. Regardless 
of diagnosis, the majority of patients receiving biologics 
resided in the most deprived areas.
From the overall cohort, a total of 89.3% of patients 
had more than one delivery of biologic during the study 
period and 83.2% did not switch biologic. Patients were 
most commonly started on adalimumab or etanercept as 
index biologic. The median days’ follow-up on biologic 
therapy, regardless of whether the patients switched to 
others biologics, was: 494 days in patients with AS; 544 
days in patients with PsA and 529 days in patients with RA.
Use of concomitant non-biologic medication during the 
study period was more frequent among patients with RA 
with oral methotrexate (54.9%), any DMARDs (81.6%) 
and NSAIDs (63.2%) most commonly prescribed. 
A similar pattern of medication use was observed in 
patients with PsA. In contrast, in patients with AS, NSAIDs 
(71.4%) were the most commonly coprescribed medica-
tions. Prescription of at least one course of antibiotics in 
patients during the study period was similar for the three 
conditions (RA: 62.5%, PsA: 59.9%, AS: 49.5%). Similar 
trends of concomitant medications were found in the 
incident cohort (see online supplementary table 1).
Discontinuation and persistence
For all three conditions, approximately half of the patients 
were persistent on their index biologic throughout the 
study period (52% AS, 54% PsA, 48% RA). This was 
also observed in the incident cohort (55% AS, 55% PsA, 
49% RA) as shown in figure 2 for the overall cohort and 
online supplementary figure 2.
Some patients after a period of discontinuation reiniti-
ated the same biologic received at the index date (overall 
cohort 19% AS, 18% PsA and 21% RA; incident cohort 
18% AS, 18% PsA, 19% RA).
A small proportion of patients switched. There were 
patients changing their index to another biologic either 
while being persistent (overall cohort 4% AS, 9% PsA 
and 5% RA; incident cohort 4% AS, 9% PsA and 6% RA) 
or reinitiating after a discontinuation, with a gap longer 
than 56 days between deliveries (overall cohort 7% AS, 
4% PsA and 1% RA; incident cohort 5% AS, 3% PsA and 
1% RA).
The remaining patients had a discontinuation and 
ceased treatment, meaning they did not restart a subcu-
taneous biologic during the study period (overall and 
incident cohort 18% AS, 15% PsA and 25% RA). A sensi-
tivity analysis was conducted using a gap of 28 and 84 days 
showing similar trends (results for overall and incident 
cohorts are in online supplementary figure 3).
The crude survival curve of time to discontinuation (first 
gap greater than 56 days between biologic deliveries) of 
any biologic is shown in figure 3. In the crude model, the 
proportion of patients persisting is slightly higher in PsA 
and AS compared with RA; however, there is no signifi-
cant difference according to the log-rank test (p=0.0983). 
The same results were observed in the incident cohort 
(p=0.165; online supplementary figure 4). The PH 
assumption was not violated with all the patients (global 
p=0.757) or in the incident cohort (global p=0.953).
After adjustment for covariates, there was a slight 
difference between patients with RA and PsA (HR=0.71, 
95% CI 0.54 to 0.95, p=0.02). Lower risk of discontinua-
tion was associated with the two least deprived quintiles 
(SIMD 4 or 5), whereas female sex and SIMD 3 (deprived 
quintile) were associated with a higher risk of discontin-
uation as shown in figure 4. Age, SIMD 2 (more deprived 
quintile), prior use of of oral methotrexate, concomitant 
use of oral methotrexate or DMARD were not statistically 
signficant covariates and did not influence the model, 
which excluded 21 patients with missing SIMD values. 
A subanalysis was performed with the incident cohort in 
which there was no longer a difference between sex and 
SIMD 4; however, the results of rheumatic conditions and 
SIMD 3 and SIMD5 quintiles remained significant (see 
online supplementary figure 5). As those who used the 
index biologic or switched was used as a stratifying vari-
able, no effect size is estimated for this covariate. The PH 
assumption was not violated when estimating the adjusted 
model with all the patients (global p=0.545) or the inci-
dent cohort (global p=0.192).
Adherence
Patients with at least two deliveries of the first (index) 
biologic (n=671, 89.3%) were used to evaluate adher-
ence, calculated using two methods.
Overall adherence during the period of treatment 
was over 80% when calculated using either the MRA or 
CR. However, this was consistently higher using %CR 
(median (IQR) for AS 96.6% (86.6–103.5), PsA 97% 
(85.5–103.2) and RA 96.6% (85.9–102.7) than using 
%MRA (median(IQR) for AS 84.0% (54.73–94.74), PsA 
85.0% (50.76–98.25) and RA 82.4% (47.24–95.77)). The 
same pattern was also observed when comparing these 
two methods by the first biologic received (figure 5A,B). 
Regardless of which of the two measurements were used, 
the few patients with PsA (n=7) taking ustekinumab had 
higher adherence than was seen with any other biologic. 
Similar adherence results were obtained in the subset 
with incident users (online supplementary figure 6).
DIsCussIOn
This study is the first real-world cohort using data about 
SC biologic deliveries, combined with routine data from 
rheumatology clinics, community pharmacy dispensing, 
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Table 1 Baseline characteristics of patients with rheumatic conditions receiving subcutaneous biologics from January 
2012 to May 2015 (n=751)
Rheumatic disease All
Ankylosing 
spondylitis Psoriatic arthritis
Rheumatoid 
arthritis P value
n 751 105 227 419
Female, n (%) 497 (66.2) 35 (33.3) 130 (56.5) 332 (78.7) 2.2×10−16
Age*
  Age (median, IQR)* 53.0 (42.7–60.9) 47.2 (35.4–55.0) 48.0 (40.2–57.3) 56.0 (47.4–64.2) 4.3×10−14
Age by category 5.3×10−12
  18–34 (%) 93 (12.4) 24 (22.9) 36 (15.9) 33 (7.9)
  35–49 (%) 222 (29.6) 36 (34.3) 91 (40.1) 95 (22.7)
  50–64 (%) 313 (41.7) 36 (34.3) 82 (36.1) 195 (46.5)
  65+ (%) 123 (16.4) 9 (8.6) 18 (7.9) 96 (22.9)
SIMD† 0.326
  1 most deprived (%) 305 (40.6) 42 (42.9 93 (42.1 170 (41.5
  2 (%) 132 (17.6) 21 (21.4) 44 (19.9) 67 (16.3)
  3 (%) 81 (10.8) 13 (13.3) 23 (10.4) 45 (11)
  4 (%) 93 (12.4) 15 (15.3) 25 (11.3) 53 (12.9)
  5 least deprived (%) 118 (15.7) 7 (7.1) 36 (16.3) 75 (18.3)
Number of deliveries of biologics
  Number of deliveries of 
biologics (median, IQR)
6 (3-12) 7 (3-11) 6 (3-12) 6 (3-12) 0.579
Number of deliveries of 
biologics by category (%)
0.752 
  1 80 (10.7) 14 (13.3) 19 (8.4) 47 (11.2)
  2–10 456 (60.7) 59 (56.2) 141 (62.1) 256 (61.1)
  11–20 156 (20.8) 25 (23.8) 49 (21.6) 82 (19.6)
  21+ 59 (7.8) 7 (6.7) 18 (7.9) 34 (8.1)
Number of different biologics delivered (%) 0.108 
  1 625 (83.2) 89 (84.8) 179 (78.9) 357 (85.2)
  2, 3 or 4 (switchers) 126 (16.8) 16 (15.2) 48 (21.1) 62 (14.8)
First biologic delivered (%) 8.3×10−13
  Adalimumab 305 (40.6) 55 (52.4) 112 (49.3) 138 (32.9)
  Certolizumab Pegol 77 (10.3) 6 (5.7) <5 69 (16.5)
  Etanercept 240 (32) 24 (22.9) 82 (36.1) 134 (32)
  Golimumab 93 (12.4) 20 (19) 24 (10.6) 49 (11.7)
  Abatacept 8 (1.1) NA NA 8 (1.9) NA‡
  Tocilizumab 21 (2.8) NA NA 21 (5)
  Ustekinumab 7 (0.9) NA 7 (3.1) NA
  Follow-up (days), median 
(IQR)
529 (284.0–852.0) 494 (285–838) 544 (280–831) 529 (283.5–866.5) 0.894
Concomitant medication use within one year before index date (%) 6.8×10−3
  Antibacterial use 48 (6.4) 6 (5.7) 11 (4.8) 31 (7.4)
  Oral methotrexate use 89 (11.9) <5 23 (10.1) 63 (15)
  Any DMARD 115 (15.3) <5 28 (12.3) 84 (20)
  NSAID 114 (15.2) 17 (16.2) 28 (12.3) 69 (16.5)
  Gluco or corticosteroids 19 (2.5) <5 <5 16 (3.8)
  Antifungal use <10 NA <5 6 (1.4) NA‡
Continued
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hospital discharges and mortality records to assess the 
utilisation of biologics in patients with RA, AS and PsA 
over a period of 3 years. This study found for all three 
conditions, approximately 50% of the patients were 
persistent on their index biologic and that overall adher-
ence during the period of treatment was over 80%. Almost 
Rheumatic disease All
Ankylosing 
spondylitis Psoriatic arthritis
Rheumatoid 
arthritis P value
  Antiviral use <5 NA NA <5
  Subcutaneous 
methotrexate use
NA NA NA NA
Concomitant medication use during study period (%) 1.0×10−7
  Antibacterial use 450 (59.9) 52 (49.5) 136 (59.9) 262 (62.5)
  Antifungal use 72 (9.6) 9 (8.6) 26 (11.5) 37 (8.8)
  Antiviral use 53 (7.1) <5 17 (7.5) 34 (8.1)
  Oral methotrexate use 332 (44.2) 10 (9.5) 92 (40.5) 230 (54.9)
  Any DMARD 493 (65.6) 12 (11.4) 139 (61.2) 342 (81.6)
  NSAID 491 (65.4) 75 (71.4) 151 (66.5) 265 (63.2)
  Gluco or corticosteroids 148 (19.7) 10 (9.5) 29 (12.8) 109 (26)
Subcutaneous methotrexate 
use
14 (1.9) NA <5 11 (2.6) NA‡
Comorbidities (%)§
  Charlson score <2.2×10−16
   0 163 (21.7) 38 (36.2) 75 (33) 50 (11.9)
   1 190 (25.3) – – 167 (39.9)
   2+ 34 (4.5) – – 28 (6.7)
   Unknown 364 (48.5) 58 (55.2) 132 (58.1) 174 (41.5)
*Age at first delivery,
†From 751 patients, 22 did not have Scottish Index of Multiple Deprivation (SIMD) values. Follow-up is from first delivery to study end date.
‡Comparison was not calculable because numbers in some cells were not available, were zero and/or too small.
§Following the statistical disclosure protocol of the Greater Glasgow and Clyde Safe Haven to avoid attribute disclosure, the cell suppression 
(primary and secondary) method was used for values in the comorbidities section as some were too small.
DMARD, disease-modifying antirheumatic drugs; NSAID, non-steroidal anti-inflammatory drug.
Table 1 Continued
Figure 2 Persistence and discontinuation (reinitiating or ceasing) of treatment with biologics according to rheumatic condition 
(n=751).
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half of patients who discontinued their index biologic for 
a period greater than 56 days ultimately reinitiate the 
same therapy with only a minority switching to another 
biologic. This highlights the importance of longitudinal 
data as many of these patients would have been incor-
rectly counted as cessations in other datasets.
A diverse range of studies have reported on the use of 
biologics over the last 20 years with the majority focused 
solely on RA,19 29 43 and few studies comparing utilisa-
tion across the three main inflammatory rheumatolog-
ical conditions within a single healthcare system. Patient 
demographic characteristics in our study are similar to 
those reported in other epidemiological studies in the 
UK, Denmark, Norway and Germany,11–16 despite the 
different methodologies used to create these cohorts.
Linked prescription and administrative health datasets 
have been used to study the utilisation of biologics in real-
world settings in other studies in Europe, USA, Canada 
and Brazil.24 28 29 44 45 However, to the best of our knowl-
edge, this is the first study to use routine data generated 
through ‘direct to home’ deliveries of biologics as a source 
of information to assess how patients use these medicines. 
Most other routine administrative healthcare studies use 
prescriptions or claims/reimbursement data. In contrast, 
this homecare delivery service requires active participa-
tion of the patient in both ordering and then signing for 
receipt of the biologic, thereby confirming the biologic 
was prescribed, the prescription was processed and the 
patient received the biologic, providing better insight 
into how patients are using their medicines.
To understand the use of medicines in our cohort, we 
adopted the taxonomy proposed by ESPACOMP.27 In 
summary, the framework enables us to quantify a patient’s 
medicine-taking behaviour in three respects: intensity, 
continuity and duration—how much of a drug does a 
patient take, how frequently, and for how long? Persistence 
and discontinuation allow us to study continuity and dura-
tion of treatment, while adherence enables us to study 
intensity of treatment in the context of the prescribed 
treatment regimen.
In those studies that examined persistence and discon-
tinuation with biologics across rheumatic conditions, 
using a consistent in-study method over a comparable 
time period to our study, persistence was reported as 
being lower in RA than AS.45 46 This is similar to our find-
ings where patients with RA were most likely to discon-
tinue their index subcutaneous biologic, potentially 
reflecting the treat-to-target approach and greater ther-
apeutic options available for RA at the time of this study. 
Our study also enabled quantification and categorisation 
of biologic switching, we believe for the first time, in both 
patients who were persistent regardless of changes in 
therapy and those who discontinued index therapy and 
then commenced a new biologic (figure 1).
In our Cox regression analyses, female sex was associ-
ated with lower persistence being consistent with several 
studies.43 45 46 However, our findings regarding socieco-
nomic status contradict those of the Machado et al study 
as we have shown higher persistence in patients with 
lower deprivation levels. There are also discrepancies in 
the association with the use of methotrexate, as Heiberg 
et al reported a strong association of its concomitant use 
with persistence in the three rheumatic diseases and we 
did not find an association. Randomised controlled trials 
of biologics in patients with PsA have failed to demon-
strate superiority of combination therapies.47 48 Thus, 
the role of methotrexate as a predictor for persistence 
remains unclear.
Persistence after the first, second or subsequent 
courses of biologics is still controversial. A French study 
found better persistence with first biologic compared 
with second or third,49 with similar tendencies reported 
in Norway by Heiberg et al. In contrast, in a large UK 
national cohort of patients with RA, those who switched 
to a second biologic had higher persistence,50 and the 
study using the Rheumatoid Arthritis Disease-Modifying 
Anti-Rheumatic Drug Intervention and Utilization Study 
(RADIUS) registry found similar persistence between first 
and second biologic.51 In our study instead of comparing 
each course, we compared those persisting with their 
index biologic (first biologic) with those persisting after 
switching. Our findings were similar to the UK cohort as 
persistence was higher in those who had switched.
Various studies have examined adherence in a single 
rheumatoid condition, often RA,18–24 26–29 but we could 
only find a single Italian study measuring adherence 
across RA, AS and PsA,44 though applying a different 
method to our study. The challenge in comparing results 
Figure 3 Crude survival curves comparing 
persistent patients according to rheumatic condition 
(n=655). AS, ankylosing spondylitis; PsA, psoriatic arthritis; 
RA, rheumatoid arthritis.
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Figure 4 Adjusted HRs for persistence with biologics using Cox regression analysis excluding patients without SIMD values 
(n=634). SIMD, Scottish Index of Multiple Deprivation quintile. 
Figure 5 Adherence to biologics by rheumatic condition according to %MRA (A) and %CR (B). CR, compliance rate; MRA, 
medication refill adherence.
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between studies is often the absence of any detail on how 
adherence was measured and where specified, multiple 
measures being used. This has been highlighted in a 
recent systematic review and meta-analysis by Schei-
man-Elazary et al18 of antiarthritis medication in RA, 
which reported adherence ranging from 10.5% to 98.5% 
with the meta-analysis generating an adherence rate 
of 66% (95% CI 58% to 75%), noting that variability 
may result from different methods and readers should 
appraise studies according to the validity of the method, 
the scales and cut-off points. From our experience of 
using both MRA and CR for adherence measurement, we 
would recommend the use of CR as it is simple to calcu-
late and includes the period between deliveries, thereby 
removing any ambiguity arising following the last supply 
of medicine.
In this study, there were cases where %MRA or %CR 
was above 100% suggesting some patients could have 
received more biologics than those expected for that 
period of time or adjustments with deliveries could be 
made later on, which were not captured in the study 
period. The higher adherence to ustekinumab compared 
with the other biologics in this study may relate in part to 
the small numbers, a more recent introduction requiring 
the delivery of two 45 mg vials to achieve the 90 mg dose 
and a shorter use of this agent at the time of the study, 
although this observation has also been reported in psori-
asis cohorts.52 53 
This current study has several strengths. This is the first 
real-world cohort containing type, frequency and dose of 
subcutaneous biologics delivered directly to patients for 
these three rheumatic diseases. The cohort is sustainable 
as it is generated as part of routine clinical care, avoiding 
the need for additional data collection burden required 
in a traditional registry model, it can be easily updated 
and linked to other administrative datasets, has better 
coverage than individually held clinical data and allows 
the use of biologics to be studied over time. The sustain-
ability is a key factor, enabling biosimilar and new future 
innovator biologics to be easily captured as these reach 
the clinic. This model can also be easily extended to other 
specialities, including dermatology and gastroenterology, 
where similar biologic therapies are used. Recording 
the confirmed delivery of drug directly to patients may 
reduce some of the uncertainty and limitations associated 
with using prescription or reimbursement administrative 
datasets where it cannot be determined if patients actually 
received the drug. Recall bias was minimised by linking 
routine data and not based on self-reported persistence 
or adherence, while selection bias was addressed by 
including all the patients receiving biologics in the largest 
Scottish Health Board.
This study also has some limitations. The cohort covers 
a specific, albeit highly populated, region in Scotland 
and the generalisability of the results has to be tested. 
It is a mixed cohort of naive and existing biologic users, 
which could influence the assessment of medication util-
isation. However, the results were similar in the overall 
and incident cohorts. By using CR as an adherence 
measurement, patients discontinuing prior to study 
completion are not considered. This was overcome in 
our study by reporting together adherence, persistence 
and discontinuation. The reasons for discontinuation 
or treatment interruption are not currently captured in 
HSD, so it is of limited utility in terms of understanding 
the factors that influence the use of biologics. History 
of biologics or subcutaneous methotrexate being used 
prior to 2012 was not available. However, during the 
study period, the use of subcutaneous methotrexate 
was captured within the HSD, recording a relatively low 
use. The biologics home delivery service only captures 
subcutaneous biologics and not intravenous agents, 
such as infliximab or rituximab, so will have missed 
where patients were switched to these agents. However, 
the latter are far smaller in volume and may be captured 
from rheumatology clinic documentation and hospital 
administrative data where attendance for infusion guar-
antees receipt of drug.
COnClusIOn
The long-term evaluation of biologics for the treatment 
of rheumatic and related diseases is a desirable goal on a 
clinical level, but it is also a requirement from a pharma-
cological and economic point of view. Traditional drug 
or disease registers are expensive, resource intensive and 
difficult to sustain, so strategies using linked administra-
tive and routine clinical data provide the best opportunity 
to capture the true picture of biologic use. Addition-
ally, a homecare delivery database may reduce some of 
the uncertainties associated with other administrative 
databases.
In moving forward, we strongly advocate that future 
studies should consider application of the ESPACOMP 
framework25 to better understand the use of biologics, 
that is, the combination of discontinuation, persistence 
and adherence metrics, thus leading to a more consis-
tent approach that enables more comparability between 
studies.
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